BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Massironi S, Fraquelli M, Paggi S, Sangiovanni A, Conte D, Sciola V, Ciafardini C, Colombo M, Peracchi M. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis. 2009;41:31-35. [PMID: 18762462 DOI: 10.1016/j.dld.2008.05.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease. Ann Surg Oncol 2010;17:2427-43. [DOI: 10.1245/s10434-010-1006-3] [Reference Citation Analysis]
2 Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plöckinger U, Salazar R. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95:135-156. [PMID: 22262080 DOI: 10.1159/000335629] [Cited by in Crossref: 259] [Cited by in F6Publishing: 189] [Article Influence: 25.9] [Reference Citation Analysis]
3 Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: Clinical application or false hopes? World J Methodol 2017; 7(1): 9-15 [PMID: 28396845 DOI: 10.5662/wjm.v7.i1.9] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
4 Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427-2443. [PMID: 20217257 DOI: 10.1245/s10434-010-1006-3] [Cited by in Crossref: 220] [Cited by in F6Publishing: 204] [Article Influence: 18.3] [Reference Citation Analysis]
5 Ramachandran R, Bech P, Murphy KG, Dhillo WS, Meeran KM, Chapman RS, Caplin M, Ghatei MA, Bloom SR, Martin NM. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol (Oxf) 2012;76:831-6. [PMID: 22175276 DOI: 10.1111/j.1365-2265.2011.04319.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
6 Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol. 2017;10:19-27. [PMID: 28223833 DOI: 10.2147/ceg.s109123] [Cited by in Crossref: 55] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
7 Livzan MA, Gaus OV, Mozgovoi SI, Bordin DS. Chronic Autoimmune Gastritis: Modern Diagnostic Principles. Diagnostics (Basel) 2021;11:2113. [PMID: 34829460 DOI: 10.3390/diagnostics11112113] [Reference Citation Analysis]
8 Szarvas T, Jardin-Watelet B, Bourgoin N, Hoffmann MJ, Nyirády P, Oláh C, Széll T, Csizmarik A, Hadaschik B, Reis H. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocr Connect 2019;8:625-33. [PMID: 30999279 DOI: 10.1530/EC-19-0068] [Reference Citation Analysis]
9 Zissimopoulos A, Vradelis S, Konialis M, Chadolias D, Bampali A, Constantinidis T, Efremidou E, Kouklakis G. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol. 2014;49:942-949. [PMID: 24897131 DOI: 10.3109/00365521.2014.920910] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
10 Youssef AA, Issa HA, Omar MZ, Behiry EG, Elfallah AA, Hasaneen A, Darwish M, Ibrahim DB. Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality. Clin Exp Gastroenterol 2018;11:431-8. [PMID: 30538523 DOI: 10.2147/CEG.S171339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America 2011;40:111-34. [DOI: 10.1016/j.ecl.2010.12.001] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 8.6] [Reference Citation Analysis]
12 Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SR. The extended granin family: structure, function, and biomedical implications. Endocr Rev. 2011;32:755-797. [PMID: 21862681 DOI: 10.1210/er.2010-0027] [Cited by in Crossref: 179] [Cited by in F6Publishing: 168] [Article Influence: 16.3] [Reference Citation Analysis]
13 Barsoum I, Elgohary MN, Bassiony MAA. Lipocalin-2: A novel diagnostic marker for hepatocellular carcinoma. Cancer Biomark 2020;28:523-8. [PMID: 32568173 DOI: 10.3233/CBM-190084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Kruljac I, Vurnek I, Maasberg S, Kust D, Blaslov K, Ladika Davidović B, Štefanović M, Demirović A, Bišćanin A, Filipović-čugura J, Marić Brozić J, Pape U, Vrkljan M. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms. Endocrine 2018;60:395-406. [DOI: 10.1007/s12020-018-1592-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Rossi RE, Garcia-Hernandez J, Meyer T, Thirlwell C, Watkins J, Martin NG, Caplin ME, Toumpanakis C. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med. 2015;3:118. [PMID: 26207246 DOI: 10.3978/j.issn.2305-5839.2015.04.23] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
16 Massironi S, Zilli A, Elvevi A, Invernizzi P. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmunity Reviews 2019;18:215-22. [DOI: 10.1016/j.autrev.2018.08.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
17 Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J Jr, Zelinka T. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel) 2019;11:E586. [PMID: 31027285 DOI: 10.3390/cancers11040586] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
18 Bech P, Martin N, Ramachandran R, Bloom S. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem 2014;51:8-21. [DOI: 10.1177/0004563213489670] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
19 Wahb AMSE, El Kassas M, Khamis AK, Elhelbawy M, Elhelbawy N, Habieb MSE. Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2021; 13(11): 1753-1765 [PMID: 34904043 DOI: 10.4254/wjh.v13.i11.1753] [Reference Citation Analysis]
20 Corsello A, Di Filippo L, Massironi S, Sileo F, Dolcetta Capuzzo A, Gemma M, Carlucci C, Cusini C, Colombo B, Dallatomasina A, Franchi GM, Corti A, Manzoni MF. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. PLoS One. 2018;13:e0196858. [PMID: 29723285 DOI: 10.1371/journal.pone.0196858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
21 Trapé J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch-Ferrer Á, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med. 2011;49:1605-1620. [PMID: 21892908 DOI: 10.1515/CCLM.2011.694] [Cited by in Crossref: 45] [Cited by in F6Publishing: 9] [Article Influence: 4.1] [Reference Citation Analysis]